NasdaqGS - Nasdaq Real Time Price USD

Design Therapeutics, Inc. (DSGN)

Compare

4.5200

-0.5550

(-10.94%)

At close: January 10 at 4:00:01 PM EST

4.5200

0.00

(0.00%)

After hours: January 10 at 4:20:00 PM EST

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: 2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK Piper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3,

GlobeNewswire last month

DSGN
-10.94%
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Se

GlobeNewswire 2 months ago

DSGN
-10.94%
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Design...

Simply Wall St. 2 months ago

DSGN
-10.94%
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Simply Wall St. 3 months ago

DSGN
-10.94%
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The

GlobeNewswire 4 months ago

DSGN
-10.94%
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 4 months ago

DSGN
-10.94%
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Key Insights Institutions' substantial holdings in Design Therapeutics implies that they have significant influence...

Simply Wall St. 4 months ago

DSGN
-10.94%
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Cash and Securities of $261.0 Million Supports Operations Through Potentially Four Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments

GlobeNewswire 5 months ago

DSGN
-10.94%
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:PIPR) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. Piper Sandler may be the best bet for investors especially when you see

InvestorPlace 7 months ago

CNTX

RVNC

ABBV
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review

Insights on Financial Performance and Future Milestones

GuruFocus.com 7 months ago

DSGN
-10.94%
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLS

GlobeNewswire 8 months ago

DSGN
-10.94%
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The

GlobeNewswire 8 months ago

DSGN
-10.94%
Independent Director of Design Therapeutics Picks Up 88% More Stock

Whilst it may not be a huge deal, we thought it was good to see that the Design Therapeutics, Inc. ( NASDAQ:DSGN...

Simply Wall St. 9 months ago

DSGN
-10.94%
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 9 months ago

DSGN
-10.94%
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript March 19, 2024 Design Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.32. DSGN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Design’s […]

Insider Monkey 9 months ago

DSGN
-10.94%
Q4 2023 Design Therapeutics Inc Earnings Call

Q4 2023 Design Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 9 months ago

DSGN
-10.94%
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington’s Disease (HD) Targeting Reduction of Mu

GlobeNewswire 9 months ago

DSGN
-10.94%
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. The event will be webcast live under the “Events” section of the Investors page o

GlobeNewswire 9 months ago

DSGN
-10.94%

Performance Overview

Return	DSGN	S&P 500
YTD	-26.74%	-1.35%
1-Year	+70.57%	+22.51%
3-Year	-74.85%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Design Therapeutics, Inc. (DSGN)

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Independent Director of Design Therapeutics Picks Up 88% More Stock

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

Q4 2023 Design Therapeutics Inc Earnings Call

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Performance Overview